← All candidates
One insider buy in the last year — $50.0K in all.
Lisa C. McClainEducation and Workforce · Financial Servicestraded 31 Oct 2025 · filed 21 Nov 2025 · spouseSold$1K–$15Kspouse31 Oct 2025321d ago21 Nov 2025300d agoLisa C. McClainEducation and Workforce · Financial Servicestraded 30 Oct 2025 · filed 21 Nov 2025 · spouseBought$1K–$15Kspouse30 Oct 2025322d ago21 Nov 2025300d ago250 filings on record.
ROIVRoivant Sciences Ltd.
NasdaqGS · Healthcare · $28.58B
$39.57
+0.18% · Sep 16
One insider buy in the last year — $50.0K in all.
Nothing in the last fortnight.
Price · 1Y · daily● 1 buy● 113 sells◆ 5 8-K
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$28.58B
Float
580.4M
80% public
Short % float
Pro
Price / profit
—
not yet profitable
Price / future profit
—
Price / sales
3794.8
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
CEO
Gline Matthew
Bought $50.0K on Sep 18 — 3,315 sh @ $15.07, held direct, 0.0% of their stake.
1 of 1 position beat the S&P
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
1 filingnewest first
Congress
▸ Disclosures lag trades by 30–45 days.
3 disclosures12 mo
MemberTradeAmountOwnerTradedFiled
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
245 more transactions on Pro →Context
Wall St
$39.38 avg target
-0.5% vs today · 12 analysts · consensus Strong Buy
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
3 of 4 quarters beat
Q1 '26−$0.32 act+$0.03
Q4 '25−$0.24 act+$0.07
Q3 '25−$0.28 act+$0.03
Q2 '25−$0.25 act−$0.02
Coverage
Assessing Roivant Sciences (ROIV) Valuation After Strong Recent Share Price MomentumSimply Wall St. · 05-26TD Cowen Raises its Price Target on Roivant Sciences (ROIV)Insider Monkey · 05-25Litigation Windfall Driving Roivant Sciences’ Profit Swing Might Change The Case For Investing In Roivant Sciences (ROIV)Simply Wall St. · 05-25Roivant (ROIV) Climbs 15% on Swing to ProfitsInsider Monkey · 05-21
The file stays open
250 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice